Regulation of autoimmune diabetes: Characteristics of non-islet-antigen specific therapies

Immunology and Cell Biology

Volumn 74, Issue 5, 1996, Pages 401-407

  Gazda, Lawrence S ^a   Baxter, Alan G ^b   Lafferty, Kevin J ^a  

^a Biology and Environment   (Australia)

^b CENTENARY INSTITUTE   (Australia)

Author keywords

Diabetes; Regulation

Indexed keywords

AUTOANTIBODY; BCG VACCINE; ERYTHROCYTE ANTIBODY; FREUND ADJUVANT; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DRUG THERAPY; ETIOLOGY; HISTOLOGY; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN;

ANIMALIA; CELL FUSING AGENT VIRUS; MYCOBACTERIUM BOVIS BCG;

EID: 0029841472     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1038/icb.1996.69     Document Type: Article

References (33)

1. + T cells in the destruction of islet grafts by spontaneously diabetic mice. Proc. Natl Acad. Sci. USA 1991: 88: 527-31.
2. Wcgmann DR, Shehadeh N, Lafferty KJ et al. Establishment of islet-specific T-cell lines and clones from islet isografts placed in spontaneously diabetic NOD mice. J. Autoimmun. 1993: 6: 517-27.
3. + islet-specific T cell clone. Science 1990; 249: 1433-6.
4. + islet-specific T cell clone. Diabetes 1992; 41: 1603-8.
5. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995; 268: 1185-8.
6. 67) prevents autoimmune diabetes in NOD mice. Diabetes 1994: 43: 1494-9.
7. Kaufman DL, Clare-Salzler M, Tian J et al. Spontaneous loss of T cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993; 366: 69-72.
8. Muir A, Peck A, Clare-Salzler M et al. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-y transcription. J Clin. Invest. 1995; 95: 628-34.
9. Tisch R, Yang X-D, Liblau RS, McDevitt HO. Administering glutamic acid dccarboxylase to NOD mice prevents diabetes. J. Autoimmun. 1994; 7: 845-50.
10. Harada M, Kishimoto Y, Makino S. Prevention of overt diabetes and insulitis in NOD mice by a single BCG vaccination. Diab. Res. Clin. Pract. 1990; 8: 85-90.
11. McIncrney MF, Pek SB, Thomas DW. Prevention of insulitis and diabetes onset by treatment with complete Freund's adjuvant in NOD mice. Diabetes 1991; 40: 715-25.
12. Sadclain MWJ, Qin H-Y, Lauzon J, Singh B. Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes 1990; 39: 583-9.
13. Shehadeh NN, Calcinaro F, Bradley BJ et al. Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet 1994; 343: 706-7.
14. Burnet FM. The Clonal Selection Theory of Acquired Immunity. Cambridge, MA: Cambridge University Press, 1959.
15. Scott J, MacKay PG, Lernmark Å. In vitro lymphocyte recognition of islet cells following in vivo priming with allogeneic murine pancreatic islets. Acta Endocrinol. 1984; 105: 87-92.
16. Lernmark A, Kanatsuna T, Patzelt C et al. Antibodies direct against the pancreatic islet cell plasma membrane. Detection and specificity. Diahetologia 1980; 19: 445-51.
17. McCullagh P. The significance of immune suppression in normal self tolerance. Immunol. Rev, 1996; 149: 127-53.
18. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr. Rev. 1994; 15: 516-42.
19. Gazda LS, Gilchrist KA, Lafferty KJ. Autoimmune diabetes: caught in the causality trap? Immunol. Cell Biol. 1995; 73: 549-51.
20. Baxter AG, Horsfall AC, Healey D et al. Mycobactcria precipitate an SLE-like syndrome in diabetes-prone NOD mice. Immunology 1994; 83: 227-31.
21. Cox KO, Keast D. Erythrocyte autoantibodies induced in mice immunized with rat crythrocytes. Immunology 1973; 25: 531-9.
22. Shehadeh NN, LaRosa F, Lafferty KJ. Altered cytokine activity in adjuvant inhibition of autoimmunc diabetes. J. Autoimmun. 1993; 6: 291-300.
23. Kloppel G, Heitz PU, eds. Pancreatic Pathology. Edinburgh: Churchill Livingstone, 1984.
24. Goillot E, Mutin M, Touraine JL. Sialadenitis in nonobese diabetic mice: transfer into syngeneic healthy neonates by splenic T lymphocytes. Clin. Immunol. Immunopathol. 1991; 59: 462-73.
25. Humphreys-Beher M, Brinkley L, Purushotham KR et al. Characterization of antinuclear autoantibodies present in the scrum from nonobese diabetic (NOD) mice. Clin. Immunol. Immunopathol. 1993; 68: 350-6.
26. Tisch R, McDevitt HO. Antigen-specific immunotherapy: is it a real possibility to combat T cell-mediated autoimmunity? Proc. Natl Acad. Sci. USA 1994; 91: 437-8.
27. Paterson PY, Day ED, Whitacre CC. Neuroimmunologic diseases: effector cell responses and immunoregulatory mechanisms, Immunol. Rev. 1981; 55: 89-120.
28. Hagerty DT, Alien PM. Tolerance to self and the processing and presentation of self antigens. Int. Rev. Immunol 1993; 10: 313-19.
29. Ulaeto D, Lacy PE, Kipnis DM, Kanagawa O, Unanue ER. A T cell dormant state in the autoimmune process of nonobese diabetic mice treated with complete Freund's adjuvant. Proc Natl Acad. Sci. USA 1992; 89: 3927-31.
30. Qin H-Y, Sadelain MWJ, Hitchon C, Lauzon J, Singh B. Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice. J. Immunol. 1993; 150: 2072-80.
31. Lakey JR, Singh B, Warnock GL, Elliott JF, Rajotte RV. Long-term survival of syngeneic islet grafts in BCG-treated diabetic NOD mice can be reversed by cyclophosphamide. Transplantation 1995; 59: 1751-3.
32. Rothe H, Faust A, Schade U et al. Cyclophosphamide treatment of female nonobese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferongamma, but not of interleukin-4. Diabetologia 1994; 37: 1154-8.
33. Shimada A, Charlton B, Taylor-Edwards C, Fathman CG. Beta cell destruction is a late consequence of the autoimmune process in nonobese diabetic mice. Diabetes 1996 (in press).